Cargando…

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia

Bosutinib (SKI-606) is an orally available, once-daily, dual Src and Abl kinase inhibitor with promising clinical potential in first-, second-, and third-line treatment of chronic myeloid leukemia (CML). Bosutinib effectively inhibits wild-type BCR-ABL and most imatinib-resistant BCR-ABL mutations e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amsberg, Gunhild Keller-von, Koschmieder, Steffen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594007/ https://www.ncbi.nlm.nih.gov/pubmed/23493838 http://dx.doi.org/10.2147/OTT.S19901

Ejemplares similares

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Bosutinib for Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2015)

Bosutinib in chronic myeloid leukemia: patient selection and perspectives
por: Isfort, Susanne, et al.
Publicado: (2018)

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
por: Mita, Akiko, et al.
Publicado: (2018)

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
por: Isfort, Susanne, et al.
Publicado: (2023)

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
por: Rassi, Fuad El, et al.
Publicado: (2013)

High‐grade B‐cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib
por: Takakuwa, Teruhito, et al.
Publicado: (2021)

Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects
por: Ault, Patricia S., et al.
Publicado: (2016)

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia
por: Brümmendorf, Tim H., et al.
Publicado: (2020)

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
por: Cortes, Jorge E., et al.
Publicado: (2018)

Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
por: Muresan, B., et al.
Publicado: (2021)

Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
por: Abumiya, Maiko, et al.
Publicado: (2021)

Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia
por: Garrett, May, et al.
Publicado: (2023)

Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia
por: Khoury, H J, et al.
Publicado: (2018)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
por: Hochhaus, Andreas, et al.
Publicado: (2020)

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
por: Cortes, Jorge E., et al.
Publicado: (2018)

Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations
por: Sweet, Kendra, et al.
Publicado: (2014)

Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase
por: Takatsuka, Ibuki, et al.
Publicado: (2022)

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
por: Brümmendorf, Tim H., et al.
Publicado: (2022)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

Successful Bosutinib Experience in an Elderly Acute Lymphoblastic Leukemia Patient with Suspected Central Nervous System Involvement Transformed from Chronic Myeloid Leukemia
por: Atilla, Erden, et al.
Publicado: (2015)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

A retrospective observational research study to describe the real‐world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands
por: Claudiani, Simone, et al.
Publicado: (2022)

Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial
por: Réa, Delphine, et al.
Publicado: (2023)

PB1966: THE EFFECT OF BODY MASS INDEX ON THE SAFETY OF BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A POST HOC POOLED DATA ANALYSIS
por: Isfort, Susanne, et al.
Publicado: (2023)

Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study
por: Ono, Takaaki, et al.
Publicado: (2022)

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report
por: Komeno, Yukiko, et al.
Publicado: (2017)

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
por: Brümmendorf, Tim H., et al.
Publicado: (2015)

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2018)

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain
por: Levinson, Nicholas M., et al.
Publicado: (2012)

Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
por: Haslam, Sonya
Publicado: (2005)

Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia
por: Brehme, Marc, et al.
Publicado: (2016)

P676: UPDATED RESULTS FROM THE TRIAL ITCC-054/COG-AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA
por: Brivio, Erica, et al.
Publicado: (2023)

Drug Target Optimization in Chronic Myeloid Leukemia Using Innovative Computational Platform
por: Chuang, Ryan, et al.
Publicado: (2015)

Pregnancy outcomes in patients treated with bosutinib
por: Cortes, Jorge E, et al.
Publicado: (2020)

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
por: Brümmendorf, Tim H, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9mp4tfihq127lc1ncuuqaru1si